Viridian Therapeutics, Inc. VRDN Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s cash ratio?
- Viridian Therapeutics, Inc. (VRDN) reported cash ratio of 3.4× in Q1 2026.
- How has Viridian Therapeutics, Inc.'s cash ratio changed year-over-year?
- Viridian Therapeutics, Inc.'s cash ratio decreased by 1.2% year-over-year, from 3.4× to 3.4×.
- What is the long-term trend for Viridian Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s cash ratio has grown at a -6.9% compound annual growth rate (CAGR), from 4.3× to 3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.